Haynes Lab:Notebook/Synthetic Biology and Bioinformatics for Predictable Control of Therapeutic Gene2/2012/11/16
From OpenWetWare
(Difference between revisions)
(→Genes of Focus) |
(→Genes of Focus) |
||
| (3 intermediate revisions not shown.) | |||
| Line 7: | Line 7: | ||
<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### --> | <!-- ##### DO NOT edit above this line unless you know what you are doing. ##### --> | ||
==Genes of Focus== | ==Genes of Focus== | ||
| + | There is a threshold of > 10^-3 | ||
| + | <br/> | ||
'''HepG2''' | '''HepG2''' | ||
*TBD | *TBD | ||
'''K562''' | '''K562''' | ||
<br/> | <br/> | ||
| - | + | ''MAP Kinase Activity'' | |
<br/> | <br/> | ||
1. MAPK14 | 1. MAPK14 | ||
| Line 20: | Line 22: | ||
3. MAPK10 | 3. MAPK10 | ||
*Through its phosphorylation and nuclear localization, this kinase plays regulatory roles in the signaling pathways during neuronal apoptosis | *Through its phosphorylation and nuclear localization, this kinase plays regulatory roles in the signaling pathways during neuronal apoptosis | ||
| - | + | ''Phosphotransferase activity, alcohol group as acceptor'' | |
| - | + | <br/> | |
| + | 4. RET | ||
| + | *This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. | ||
| + | *Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. | ||
| + | 5. FGFR4 | ||
| + | *This particular family member preferentially binds acidic fibroblast growth factor and, although its specific function is unknown, it is overexpressed in gynecological tumor samples, suggesting a role in breast and ovarian tumorigenesis. | ||
| + | 6. CDK1A | ||
| + | *The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. | ||
| + | *The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. | ||
| + | *Plays a regulatory role in S phase DNA replication and DNA damage repair. | ||
| + | *May be instrumental in the execution of apoptosis following caspase activation. | ||
'''SK-N-SH RA''' | '''SK-N-SH RA''' | ||
| - | + | <br/> | |
| + | ''Signaling receptor activity'' | ||
| + | <br/> | ||
| + | 1. KIT | ||
| + | *This gene encodes the human homolog of the proto-oncogene c-kit. C-kit was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. | ||
| + | *Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism. | ||
| + | 2. TNFRSF11A | ||
| + | *TNF-receptor superfamily (tumor necrosis factor) | ||
| + | 3. EGFR | ||
| + | *Mutations in this gene are associated with lung cancer. | ||
| + | ''Sequence-Specific DNA Binding'' | ||
| + | <br/> | ||
| + | 4. WT1 | ||
| + | *It is mutated in a small subset of patients with Wilm's tumors | ||
| + | 5. HLF | ||
| + | *Chromosomal translocations fusing portions of this gene with the E2A gene cause a subset of childhood B-lineage acute lymphoid leukemias. | ||
| + | 6. BCL6 | ||
| + | *This gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. | ||
<!-- ##### DO NOT edit below this line unless you know what you are doing. ##### --> | <!-- ##### DO NOT edit below this line unless you know what you are doing. ##### --> | ||
|} | |} | ||
Revision as of 14:44, 19 November 2012
Main project page Previous entry Next entry
| |
Genes of FocusThere is a threshold of > 10^-3
K562
2. MAPK9
3. MAPK10
Phosphotransferase activity, alcohol group as acceptor
5. FGFR4
6. CDK1A
SK-N-SH RA
2. TNFRSF11A
3. EGFR
Sequence-Specific DNA Binding
5. HLF
6. BCL6
| |



